Understanding the
Unmet Need
Major Safety and
Tolerability Challenges Unnecessary Exposure to
Extended Endocrine Therapy Side Effects Lead
to Noncompliance
About Breast Cancer Index (BCI)
About BCI How is BCI Used? Predictive Studies Prognostic Studies Health Economics Study
Patient Scenarios Ordering Information Videos News & Press
bioTheranostics Privacy Statement Terms and Conditions Site Map

bioTheranostics, Inc.
9640 Towne Centre Drive | Suite 200
San Diego, CA 92121
bioTheranostics.com

US and International: +1 (858) 587-5870
Fax: +1 (858) 587-5874
Client Services: +1 (877) 886-6739
Billing Information: +1 (858) 682-9279

© 2015 bioTheranostics, Inc.
Breast Cancer Index and BCI are service marks of bioTheranostics, Inc.

< Back

Tour the Test Report

Prognostic Score

  • 0 - 10
  • Individualized risk of late recurrence*

*If ordered at time of diagnosis, test report also provides overall (years 0-10), early (0-5 year), and late (5-10 year) risk of recurrence

Prognostic Study PROGNOSTIC STUDIES

Predictive Score

  • Predictive of likelihood of benefit from extended endocrine therapy
  • HIGH or LOW (binary result)
Predictive Study PREDICTIVE STUDIES

Patient Scenarios

BCI may benefit patients throughout the treatment journey.

Select a patient to read a full case.

At Dx

For Patients

  • Struggling with tolerability challenges
  • Who are poorly compliant

BCI May Help:

  • Provide clarity on treatment road-map (5 or 10 years); encourage compliance
At
Year 5

For Patients

  • All patients approaching 5 year
    anniversary (4-5 years post-diagnosis)

BCI May Help:

  • Further inform previous decision related to extended endocrine
    treatment:
    - To continue    - To restart
At
Year 10

For Patients

  • All patients 5-9 years post-diagnosis who are either:
  • Already on extended endocrine treatment
  • Have already stopped endocrine therapy after completing 5 years.

BCI May Help:

  • Provide clarity on treatment road-map (5 or 10 years); encourage compliance

Do you have an interesting case
you would like us to consider?

Please email us at marketing@biotheranostics.com

Order BCI

References

  1. Sgroi DC, et al. Lancet Oncol. 2013;14:1067 – 76.
  2. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.
  3. Zhang Y, et al. Clin Cancer Res. 2013;19:4196-4205.

Breast Cancer Index Indications for Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.